24070-77-7

Usage

Uses

Used in Organic Synthesis:
2-Methylcyclopentanol is used as a solvent in various organic synthesis processes for its ability to dissolve a wide range of organic compounds. Its solubility properties make it a valuable component in the production of various chemicals and pharmaceuticals.
Used in Chemical Reactions:
As a reagent, 2-Methylcyclopentanol plays a crucial role in facilitating specific chemical reactions, particularly in the synthesis of complex organic molecules. Its presence can influence reaction rates and product yields, making it an essential component in many laboratory and industrial settings.
Used in the Fragrance and Flavor Industry:
Although its applications are minor compared to its use in organic synthesis, 2-Methylcyclopentanol is also utilized in the fragrance and flavor industry. Its mild odor and unique chemical properties contribute to the creation of various scents and flavors in consumer products.

InChI:InChI=1/C6H12O/c1-5-3-2-4-6(5)7/h5-7H,2-4H2,1H3/t5-,6-/m0/s1

Upstream product

• 764-59-0 hex-5-en-1-al 
• 96-37-7 methyl-cyclopentane 
• 627-93-0 hexanedioic acid dimethyl ester 

Downstream Products

• 93568-15-1 2-methylcyclopentyl 4-methylbenzenesulfonate 
• 1120-72-5 2-Methylcyclopentanone 
• 338460-07-4 2-methyl-1-cyclopentenol 
• 1523-79-1 2-methyl-cyclopentanone-(2,4-dinitro-phenylhydrazone) 
• 798571-80-9 (1-methyl-cyclopentyl)-phenyl sulfone 
• 741269-79-4 (1-methyl-cyclopentyl)-phenyl sulfide 
• 1638-95-5 1-Methyl-cyclopentanthiol 
• 93997-05-8 1,4-bis-(1-methyl-cyclopentyl)-benzene 
• 20049-04-1 (+)-(2S)-2-methyl-2-phenylcyclopentane 
• 693-89-0 1-methylcyclopent-1-ene 
• 874001-93-1 (2-methyl-cyclopentyl)-phenethyl-malonic acid 
• 872291-93-5 2-(2-methyl-cyclopentyl)-4-phenyl-butyric acid 
• 116530-98-4 optically inactive (2-methyl-cyclopentyl)-acetic acid 

Relevant academic research and scientific papers

Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Method for producing 1,6-hexanediol

A process for producing 1,6-hexanediol by hydrogenation of adipic esters and/or 6-hydroxycaproic esters in the gas phase at elevated temperature and elevated pressure in the presence of chromium-free catalysts comprises hydrogenating a) over a catalyst comprising copper, manganese and aluminum as essential constituents or over Raney copper, b) at a temperature of from 150 to 230° C. and a pressure of from 10 to 70 bar, c) at a molar ratio of hydrogen to ester to be hydrogenated within the range from 150:1 to 300:1, and d) at a catalyst space velocity of from 0.01 to 0.3 kg of C6ester per liter of catalyst per hour.

Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Compounds for inhibiting β-amyloid peptide release and/or its synthesis

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis.

Compounds for inhibiting β-amyloid peptide release and/or its synthesis

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis.

N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use

Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

FUNCTIONALISATION OF SATURATED HYDROCARBONS. Part X. A COMPARATIVE STUDY OF CHEMICAL AND ELECTROCHEMICAL PROCESSES (GIF AND GIF-ORSAY SYSTEMS) IN PYRIDINE, IN ACETONE AND IN PYRIDINE-CO-SOLVENT MIXTURES

Six saturated hydrocarbons (cyclohexane, 3-ethylpentane, methylcyclopentane, cis- and trans-decalin and adamantane) were oxidised by the Gif system (iron catalyst, oxygen, zinc, carboxylic acid) and its electrochemical equivalent (Gif-Orsay system).Results obtained using various solvents (pyridine, acetone, pyridine-acetone mixtures) were similar for both systems.Total or partial replacement of pyridine with acetone affects the selectivity for secondary positions and lowers the ketone/secondary alcohol ratio.The formation of the same ratio of cis- and trans-decal-9-ol from both cis- and trans-decalin clearly demonstrates that tertiary alcohols result from a mechanism essentially radical in nature.

Reductive, Radical-Induced Cyclizations of 5-Hexenals as a Biomimetic Model of the Chemistry of Secologanin Formation

A model reaction for studying the mechanism of the biological conversion of the iridoid loganin (1) to the secoiridoid secologanin (2) is the reductive, radical-induced cyclization of secologanin tetraacetate (4) to loganin tetraacetate.Treatment of 4 with Mg and Me3SiCl in THF at room temperature gives a mixture of the four possible C-6 and C-7 epimers of loganin tetraacetate in which the natural stereochemistry predominates.This result suggests that the biochemical event, which involves cleavage of the C-6 and C-7 bond of 1 in forming 2, may be a homolytic process that is initiated by formation of a carbon radical at C-8.The scope of the cyclization reaction, which formally occurred in a 5-hexanal moiety in 4, is defined by studies of the cyclization of six other δ,ε-unsaturated aldehydes.The results illustrate a new way for ring annulation through the reductive, radical-induced cyclization of δ,ε-unsaturated aldehydes.